Suppr超能文献

化学合成长肽的结构表征普遍缺乏。

General lack of structural characterization of chemically synthesized long peptides.

机构信息

Institut de Recherches Internationales Servier, 50 rue Carnot, 92284, Suresnes-Cedex, France.

Faculté de Pharmacie 3, rue du Professeur Laguesse, BP83 - 59006, Lille-Cedex, France.

出版信息

Protein Sci. 2019 May;28(5):857-867. doi: 10.1002/pro.3601. Epub 2019 Mar 25.

Abstract

Many peptide chemistry scientists have been reporting extremely interesting work on the basis of chemical peptides for which the only characterization was their purity, mass, and biological activity. It seems slightly overenthusiastic, as many of these structures should be thoroughly characterized first to demonstrate the uniqueness of the structure, as opposed to the uniqueness of the sequence. Among the peptides of identical sequences in the final chemical preparation, what amount of well-folded peptide supports the measured activity? The activity of a peptide preparation cannot prove the purity of the desired peptide. Therefore, greater care should be taken in characterizing peptides, particularly those coming from chemical synthesis. At a time when the pharmaceutical industry is changing its paradigm by moving substantially from small molecules to biologics to better serve patients' needs, it is important to understand the limitations of the descriptions of these products and to start to apply the same "good laboratory practices" to our peptide research. Here, we attempt to delineate how synthetic peptides are described and characterized and what will be needed to describe them in regards to how they are well-folded and homogeneous in their tertiary structure. Older studies were done when the tools were not yet discovered, but more recent publications are still lacking proper descriptions of these peptides. Modern tools of analysis are capable of segregating folded and unfolded peptides, even if the preparation is biologically active.

摘要

许多肽化学科学家一直在报告基于化学肽的非常有趣的工作,这些化学肽唯一的特征是它们的纯度、质量和生物活性。这似乎有点过于热情,因为首先应该彻底表征许多这些结构,以证明结构的独特性,而不是序列的独特性。在最终化学制剂中具有相同序列的肽中,有多少折叠良好的肽支持所测量的活性?肽制剂的活性不能证明所需肽的纯度。因此,在表征肽时应更加小心,特别是那些来自化学合成的肽。在制药行业通过从小分子实质性转变为生物制剂以更好地满足患者需求来改变其范例的时代,了解这些产品描述的局限性并开始将相同的“良好实验室规范”应用于我们的肽研究非常重要。在这里,我们试图描绘如何描述和表征合成肽,以及在它们在三级结构中折叠良好且均匀时需要描述它们的内容。当还没有发现工具时进行了较早的研究,但最近的出版物仍然缺乏对这些肽的适当描述。即使制剂具有生物活性,现代分析工具也能够分离折叠和未折叠的肽。

相似文献

5
Rapid total synthesis of DARPin pE59 and barnase.DARPin pE59 和 barnase 的快速全合成。
Chembiochem. 2014 Mar 21;15(5):721-33. doi: 10.1002/cbic.201300797. Epub 2014 Mar 11.
10
Protecting Groups in Peptide Synthesis.保护基在肽合成中的应用。
Methods Mol Biol. 2020;2103:111-128. doi: 10.1007/978-1-0716-0227-0_7.

本文引用的文献

1
Native Mass Spectrometry: What is in the Name?原生质谱:名称有何含义?
J Am Soc Mass Spectrom. 2017 Jan 1;28(1):5-13. doi: 10.1021/jasms.8b05378.
2
Native chemical ligation in protein synthesis and semi-synthesis.蛋白质合成和半合成中的天然化学连接。
Chem Soc Rev. 2018 Dec 21;47(24):9046-9068. doi: 10.1039/c8cs00573g. Epub 2018 Nov 12.
5
Xenoprotein engineering via synthetic libraries.通过合成文库进行异源蛋白工程。
Proc Natl Acad Sci U S A. 2018 Jun 5;115(23):E5298-E5306. doi: 10.1073/pnas.1722633115. Epub 2018 May 21.
9
Semaglutide: First Global Approval.司美格鲁肽:全球首次获批。
Drugs. 2018 Feb;78(2):275-284. doi: 10.1007/s40265-018-0871-0.
10
Non-protein biologic therapeutics.非蛋白类生物治疗药物。
Curr Opin Biotechnol. 2018 Oct;53:65-75. doi: 10.1016/j.copbio.2017.12.014. Epub 2017 Dec 28.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验